No profile data available.
ProKidney Corp. (PROK) is a healthcare company in the urinary system treatment drugs industry, based in Winston-Salem, United States, with about 231 full-time employees.
It reported revenue of $893,000 for fiscal year 2025, up 1075.0% from fiscal year 2024, and net income of -$68.99 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $150,000, down 32.1% from a year before. Its market capitalization was $694.58 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
ProKidney reported $893,000 in revenue for fiscal year 2025, up 1075.0% from $76,000 in fiscal year 2024. In Q2 2026 revenue was $150,000.
$694.58 million as of October 9, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Travere Therapeutics, Inc. (TVTX), Vera Therapeutics, Inc. (VERA), Akebia Therapeutics, Inc. (AKBA), Jyong Biotech Ltd. (MENS).